/CNW/ - Soricimed Biopharma Inc., ("Soricimed" or "the Company"), a clinical stage company focused on the development and commercialization of first-in-class.
The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.
Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector.
/PRNewswire/ Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an update on.